RxDoctor Payments Data

Darcy Wooten, MD

Infectious Disease · Saint Louis, MONPI 1538495973

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.9%), grants and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Viiv Healthcare Company at 53.1% of the total. Reporting peaked in 2023 at $4,570 and has fallen 97.3% since, to $123 in 2025. Among infectious disease clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,598in general payments, 2019–2025

Across 147 payments — averaging $58.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$5K
  • Janssen Scientific Affairs, LLC$3K
  • Johnson & Johnson$973
  • Astellas Pharma US Inc$177
  • La Jolla Pharmaceutical Company$98
  • Merck$26
  • plus $23 from 1 others

What the payments were for

  • Consulting fees$4,55053%
  • Grants$2,73732%
  • Food & beverage$1,10913%
  • Education$2032%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,598 in reported general payments places this provider in the 90th percentile of 177 infectious disease providers in Missouri.

See all infectious disease providers in Missouri

Medicare billing

Part B allowed, 2024
$23,307
Medicare patients
76
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala181$718,644
DovatoDolutegravir Sodium/Lamivudine49$147,504
TivicayDolutegravir Sodium50$111,140
CabenuvaCabotegravir/Rilpivirine17$97,135
GenvoyaElviteg/Cob/Emtri/Tenof Alafen17$64,884
DescovyEmtricitabine/Tenofov Alafenam27$57,985
PifeltroDoravirine31$50,255
TriumeqAbacavir/Dolutegravir/Lamivudi14$49,726
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$40,437
MounjaroTirzepatide19$18,677
Spiriva HandihalerTiotropium Bromide18$9,462
Effexor XrVenlafaxine Hcl13$7,422
EliquisApixaban12$6,788
Testosterone17$4,906
Lidocaine16$1,828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay, Cabenuva, Triumeq$4,565$405,505130 claims
MerckPifeltro$26$50,25531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 infectious disease providers in Missouri.

Other infectious disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →